PREterM FOrmula Or Donor Breast Milk for Premature Babies

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

103 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-02

Study Completion Date

2020-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In order to address this crucial question, central to preterm newborn care, a multicentre United Kingdom (UK) -wide study randomising 4000 preterm babies would be necessary to achieve sufficient power to evaluate the impact on the short-term outcomes necrotising enterocolitis and bloodstream infection, and establish cohorts large enough to address long-term metabolic (such as obesity, type 2 diabetes), cardiovascular (such as blood pressure) and developmental outcomes. This pilot trial will evaluate the practicability and feasibility of such a large multicentre UK randomised controlled trial. In addition to evaluating feasibility and to ensure maximal use of resources allocated, this study will also assess outcomes that are indicative of long term metabolic health.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Human Milk Cream as a Caloric Supplement in Pre-Term Infants

NCT01487928

Prematurity

COMPLETED NA

Donor Breast Milk and Serum Ferritin Levels in Very Preterm Infants

NCT06843278

Ferritin Levels in Very Preterm Infants

COMPLETED

Donor Breast Milk and Breastfeeding Rates

NCT04572581

Breastfeeding, Exclusive Breastfeeding

COMPLETED NA

Enhancing Breast Milk Production With Domperidone in Mothers of Preterm Neonates

NCT01512225

Low Milk Supply

COMPLETED PHASE2

Effect of Breast Milk Feeding on Critically Ill Neonates

NCT05816408

Breast Feeding

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Mother's Own Milk (MOM) is recommended for preterm babies. However, on average, mothers giving birth preterm are able to provide less than half their baby's milk requirements. Standard clinical practice is to make up any shortfall in MOM with either pasteurised Human Donor Milk (HDM) or Preterm Formula (PTF). Which option is more beneficial to clinical outcomes is unknown.

Pasteurisation reduces or destroys many biologically active components and HDM, unlike PTF, is very variable in composition. Clinicians who use HDM do so primarily in the hope that despite pasteurisation it will reduce bloodstream infection and necrotising enterocolitis, a serious, devastating inflammatory disease characterised by bowel death and multisystem failure. These are two of the most feared conditions in newborn medicine as described above. Landmark nutritional trials in the early 1980's suggest positive effects of human milk on insulin sensitivity, and other metabolic outcomes. Clinicians who prefer PTF believe it benefits growth, including brain growth, and improves neurodevelopmental outcome.

Neonates born below 32 weeks gestational age will be randomised to receive fortified HDM, unfortified HDM, or PTF to make up any shortfall in MOM until 35 weeks postmenstrual age with a sample size of 22 in each group. The trial is designed to reflect current preterm feeding practice. The trial will take place in neonatal units in London and parent consent obtained within 48hr of birth. Permission will be sought for long term follow up, initially from parents (later from children themselves). Outcomes will be body composition using magnetic resonance imaging and other imaging techniques. This pilot study will specifically assess feasibility by testing 1) provision of HDM by Human Milk Banks in London 2) acceptability to parents and clinicians using feedback on trial design 3) recruitment to target and 4) retrieval of clinical data for all recruited babies form the National Neonatal Database.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adiposity Insulin Resistance Metabolomic Profile microRNA Profile

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Unfortified Human Donor Milk

Used to make up any shortfall in mother's own milk

Group Type ACTIVE_COMPARATOR

Unfortified Human donor Milk used to make up any shortfall in mother's own milk

Intervention Type OTHER

Fortified Human Donor Milk

Used to make up any shortfall in mother's own milk

Group Type ACTIVE_COMPARATOR

Fortified Human donor Milk used to make up any shortfall in mother's own milk

Intervention Type OTHER

Preterm Formula

Used to make up any shortfall in mother's own milk

Group Type ACTIVE_COMPARATOR

Preterm Formula used when there is a shortfall in mother's own milk

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Unfortified Human donor Milk used to make up any shortfall in mother's own milk

Intervention Type OTHER

Fortified Human donor Milk used to make up any shortfall in mother's own milk

Intervention Type OTHER

Preterm Formula used when there is a shortfall in mother's own milk

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Preterm infants born between 25+0 to 31+6 weeks gestational age
* Written informed consent from parents

Exclusion Criteria

* Major congenital or life threatening abnormalities or congenital abnormalities that preclude early milk feeding
* Inability to randomise infant within 48 hours

Minimum Eligible Age

25 Weeks

Maximum Eligible Age

31 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes